Compare OXBR & NVNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OXBR | NVNO |
|---|---|---|
| Founded | 2013 | 1987 |
| Country | Cayman Islands | United States |
| Employees | 4 | 33 |
| Industry | Property-Casualty Insurers | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.1M | 7.2M |
| IPO Year | N/A | N/A |
| Metric | OXBR | NVNO |
|---|---|---|
| Price | $1.59 | $11.10 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $5.00 | N/A |
| AVG Volume (30 Days) | ★ 58.8K | 12.9K |
| Earning Date | 05-11-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $80.09 | N/A |
| Revenue Next Year | $85.22 | $140.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.66 | $0.30 |
| 52 Week High | $2.85 | $13.44 |
| Indicator | OXBR | NVNO |
|---|---|---|
| Relative Strength Index (RSI) | 70.47 | 47.73 |
| Support Level | $1.51 | $9.93 |
| Resistance Level | $2.09 | $11.15 |
| Average True Range (ATR) | 0.17 | 0.72 |
| MACD | 0.03 | -0.03 |
| Stochastic Oscillator | 72.04 | 9.59 |
Oxbridge Re Holdings Ltd is a specialty property and casualty reinsurer that provides reinsurance solutions through its subsidiary. The company focuses on underwriting fully collateralized reinsurance contracts for property and casualty insurance companies in the Gulf Coast region of the United States, with an emphasis on Florida. It specializes in underwriting medium-frequency, high-severity risks where insufficient data exists to effectively analyze the risk/return profile of reinsurance contracts. The company generates revenue from three principal sources: premiums assumed from reinsurance on property and casualty business; income from investments, including unrealized gains or losses on other investments; and income from SurancePlus management fees.
enVVeno Medical Corp is a medical device company focused on the advancement of bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The company first developed the VenoValve, which was a surgical replacement venous valve. It is focused on its next-generation, non-surgical venous valve product, called the enVVe System which consists of the enVVe Valve, enVVe Delivery System, enVVe Nose Cone, the enVVe Delivery System Accessories, and the enVVe Crimping System. The enVVe System is designed to treat severe deep chronic venous insufficiency through a minimally invasive, catheter-based approach. It operates in a single segment, Medical Device development, located in a single geographic location, the United States.